Thornburg Investment Management Portfolio Manager Nicholas Anderson in Reuters

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years – limited only by their availability.

The two companies have been the primary beneficiaries of the global boom in obesity drugs, ballooning their market values and reshaping expectations not just in the healthcare industry, but also for sellers of sugary snacks, nutritional aids and packaged foods.